Abstract P5-09-29: Trastuzumab Combined with Pyrotinib and Capecitabine as Postoperative Adjuvant Therapy in Non-Pathological Complete Response HER2-Positive Early Breast Cancer Following Neoadjuvant Therapy: A Multicenter Phase II Study
Chuan Wang, Zhe Zhang, Ruizhen Luo, Zhechao Zeng, Yi Zeng(Duke University), Ruixue Huang(Central South University), Chuangui Song(Fujian Medical University), Xiangjin Chen(First Affiliated Hospital of Fujian Medical University), Lining Jia(Hebei Medical University), Zhenchuan Song(Hebei Medical University), Fangmeng Fu(Fujian Medical University), Xia Chen(Jiangsu University), Fan Yang(Second Hospital of Shandong University), Yan Yu(University of Science and Technology of China), Wenhui Guo, Yili Wang(Anhui Agricultural University), Jianqing Lin, Mengbo Lin, Guohui Han, Shunguo Lin, Guozhong Cui(Cangzhou Central Hospital), Debo Chen(Fujian Medical University), Zhong Ouyang, Sumei Yang(Zhongshan Hospital of Xiamen University)
Cited by 0
Related Papers
DNA damage response signaling pathways and targets for radiotherapy sensitization in cancer
|Signal Transduction and Targeted Therapy|2020|1.1k
Nanoparticles‐induced potential toxicity on human health: Applications, toxicity mechanisms, and evaluation models
|MedComm|2023|664
Direct Observation of Lithium Staging in Partially Delithiated LiFePO<sub>4</sub> at Atomic Resolution
|Journal of the American Chemical Society|2011|237
Novel loci and pathways significantly associated with longevity
|Scientific Reports|2016|203